Tenaya (TNYA) Q2 Loss Narrows 59%
Tenaya Therapeutics (NASDAQ:TNYA), a clinical-stage biotechnology company focused on genetic therapies for heart disease, released second-quarter results on August 6, 2025. Tenaya posted a net loss per share of $(0.14) (GAAP) for Q2 2025, narrower than the $(0.19) loss analysts had predicted. This represented a significant year-over-year improvement from a GAAP loss of $(0.34) per share in Q2 2024. The period showed meaningful drops in both research and administrative spending, a reduced net loss (GAAP), and an enhanced cash position. Continued progress in its key clinical programs and cost-saving measures were the standout themes for the period.
Source: Analyst estimates for the quarter provided by FactSet.
Tenaya Therapeutics is dedicated to developing gene therapies for life-threatening heart diseases caused by genetic mutations. Its primary candidates—TN-201 and TN-401—are designed to address hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy, two disorders with severe outcomes and limited treatment options. The company’s work targets specific genetic faults in the myocardium, the heart’s muscular tissue, using adeno-associated virus (AAV) vectors to deliver corrective DNA into affected cells.
Source Fool.com
